Cargando…
Overcoming some Limiting Factors in Tumour Immunotherapy
Immunotherapy using rat 7s antibodies against plasmacytoma 5563 in C3H mice has been measured carefully. Prior adsorption of antibodies with normal mouse tissues, and supplements of co-optable non-immunized macrophages and lymphocytes enhanced the scope of immunotherapy against established tumours....
Autores principales: | Fakhri, O., Hobbs, J. R. |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
1973
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2009036/ https://www.ncbi.nlm.nih.gov/pubmed/4724609 |
Ejemplares similares
-
Can Natural Products be Used to Overcome the Limitations of Colorectal Cancer Immunotherapy?
por: Dong, Jiahuan, et al.
Publicado: (2022) -
NASH limits anti-tumour surveillance in immunotherapy-treated HCC
por: Pfister, Dominik, et al.
Publicado: (2021) -
Overcoming delivery barriers in immunotherapy for glioblastoma
por: Rui, Yuan, et al.
Publicado: (2021) -
Immunotherapy biomarkers 2016: overcoming the barriers
por: Gulley, James L., et al.
Publicado: (2017) -
Barriers to overcoming immunotherapy resistance in glioblastoma
por: Gillette, Julia S., et al.
Publicado: (2023)